Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 2, 2012, Pages 240-244

  Yilmaz, Yusuf ^a   Yonal, Oya ^a   Deyneli, Oguzhan ^a   Celikel, Cigdem Ataizi ^a   Kalayci, Cem ^a   Duman, Deniz Guney ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Diabetes; Dipeptidyl peptidase IV inhibitor; DPPIV; Nonalcoholic steatohepatitis; Sitagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; SITAGLIPTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY; LIVER BIOPSY; LIVER CELL; LIVER HISTOLOGY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; OPEN STUDY; PILOT STUDY; STATISTICAL SIGNIFICANCE;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY LIVER; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRAZINES; TRIAZOLES;

EID: 84863555133     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. BUTEAU J., FOISY S., JOLY E., PRENTKI M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes, 2003, 52: 124-32.
2. BUTEAU J., EL-ASSAAD W., RHODES C.J., ROSENBERG L., JOLY E., PRENTKI M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia, 2004, 47: 806-815.
3. DRUCKER D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care, 2003, 26: 2929-40.
4. LAMBEIR A.M., DURINX C., SCHARPE S., DE MEESTER I. Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci., 2003, 40: 209-94.
5. HOLST J.J. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv. Exp. Med. Biol., 2003, 524: 263-79.
6. DRUCKER D.J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert. Opin. Investig. Drugs, 2003, 12: 87-100.
7. RISTIC S., BYIERS S., FOLEY J., HOLMES D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes. Metab., 2005, 7: 692-8.
8. AHREN B., LANDIN-OLSSON M., JANSSON P.A., SVENSSON M., HOLMES D., SCHWEIZER A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89: 2078-84.
9. MARI A., SALLAS W.M., HE Y.L., WATSON C., LIGUEROSSAYLAN M., DUNNING B.E. et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2005, 90: 4888-94.
10. VERNON G., BARANOVA A., YOUNOSSI Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther., 2011, 34: 274-85.
11. BYRNE C.D., OLUFADI R., BRUCE K.D., CAGAMPANG F.R., AHMED M.H. Metabolic disturbances in non-alcoholic fatty liver disease. Clin. Sci. (Lond.), 2009, 116: 539-64.
12. VANNI E., BUGIANESI E., KOTRONEN A., DE MINICIS S., YKI-JÄRVINEN H., SVEGLIATI-BARONI G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis., 2010, 42: 320-30.
13. RAKOSKI M.O., SINGAL A.G., ROGERS M.A., CONJEEVARAM H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2010, 32: 1211-21.
14. YILMAZ Y., ATUG O., YONAL O., DUMAN D., OZDOGAN O., IMERYUZ N. et al. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease. Med. Sci. Monit., 2009, 15: HY1-5.
15. ARASE Y., SUZUKI F., KOBAYASHI M., SUZUKI Y., KAWAMURA Y., MATSUMOTO N. et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol. Res., 2011, 41: 524-9.
16. MAIZTEGUI B., BORELLI M.I., MADRID V.G., DEL ZOTTO H., RASCHIA M.A., FRANCINI F. et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin. Sci. (Lond.), 2011, 120: 73-80.
17. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care, 2006, 29: 1955-62.
18. KLEINER D.E., BRUNT E.M., VAN NATTA M., BEHLING C., CONTOS M.J., CUMMINGS O.W. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41: 1313-21.
19. TINIAKOS D.G. Nonalcoholic fatty liver disease/nonalcoholic steato-hepatitis: histological diagnostic criteria and scoring systems. Eur. J. Gastro-enterol. Hepatol., 2010, 22: 643-50.
20. BALABAN Y.H., KORKUSUZ P., SIMSEK H., GOKCAN H., GEDIKOGLU G., PINAR A. et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann. Hepatol., 2007, 6: 242-50.
21. LAKATOS P.L., FIRNEISZ G., BORCSICZKY D., ZALATNAI A., SELMECI L., SZALAY F. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur. J. Clin. Invest., 2000, 30: 793-7.
22. YANG J., CAMPITELLI J., HU G., LIN Y., LUO J., XUE C. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci., 2007, 81: 272-9.
23. FONSECA V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med., 2003, 115: 42S-8S.
24. CALDWELL S., IKURA Y., DIAS D., ISOMOTO K., YABU A., MOSKALUK C. et al. Hepatocellular ballooning in NASH. J. Hepatol., 2010, 53: 719-23.
25. LACKNER C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert. Rev. Gastroenterol. Hepatol., 2011, 5: 223-231.
26. DIXON J.B., BHATHAL P.S., HUGHES N.R., O'BRIEN P.E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology, 2004, 39 (6): 1647-54.
27. ASCHNER P., KIPNES M.S., LUNCEFORD J.K., SANCHEZ M., MICKEL C., WILLIAMS-HERMAN D.E., SITAGLIPTIN STUDY 021 GROUP. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 2006, 29: 2632-7.
28. WONG V.W., WONG G.L., CHOI P.C., CHAN A.W., LI M.K., CHAN H.Y. et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut, 2010, 59: 969-74.